Please assess the completion status of the following clinical trial:

Trial Title: Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pathologically verified primary central nervous system lymphoma No prior PCNSL treatment.~* Patients treated with steroids alone are eligible~* No signs of lymphoma outside the CNS~* ECOG performance status 0-4~* Age \> 17 and \< 76 years~* Written informed consent from the patient or guardian~Exclusion Criteria:~* Cardiac failure \> 3~* Pregnancy or lactation. Women of childbearing potential are requested to use an effective method of contraception to avoid pregnancy for a period from entry to the study and at least 3 months after the last study medication~* Previous malignancy unless disease free for at least five years~* Active infection.~* Regarding tuberculosis, patients at risk should be tested for latent TB according local practice at each treating centre.~* Positive HIV status~* Organ transplantation~* Serious psychiatric illness~* Prior radiotherapy to the brain~* Concomitant anti-inflammatory medication that cannot be discontinued~* Creatinine clearance \< 60 ml/minute calculated by Cockcroft and Gault formula~* Peripheral blood count with granulocytes \<1.5 x 109L or platelets \< 100 x 109L~* Serum bilirubin \>1.5 times or ASAT and alkaline phosphatase \>2 times upper limits of normal.~* Known anaphylaxis or IgE-mediated hypersensitivity to murine protein or any component of Rituximab excludes patients from Rituximab treatment, but not from the remaining part of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).